The Application of T1 Mapping in Real-World
The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort
1 other identifier
observational
2,000
1 country
1
Brief Summary
The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are: What are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler "native T1" measurement (without contrast dye) instead of the more complex "ECV" measurement (which requires contrast dye) for diagnosis? Patients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2020
CompletedFirst Submitted
Initial submission to the registry
December 29, 2025
CompletedFirst Posted
Study publicly available on registry
January 21, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
January 21, 2026
January 1, 2026
6.6 years
December 29, 2025
January 12, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Ranges of T1 mapping values
From enrollment until completion of the last T1 mapping examination, assessed up to 5 years
Study Arms (2)
Healthy Controls
CMR criteria: Anatomically intact cardiac structures: LVEF, ventricular volumes, and wall thickness within sex- and BSA-adjusted reference ranges (LVEF ≥55%, LVEDVi \<82 mL/m² for females, \<97 mL/m² for males); Absence of pathological tissue characteristics (negative LGE); Normal hemodynamic profile: Competent valvular function without hemodynamically significant regurgitation or stenosis. Clinical exclusion criteria: No history of coronary artery disease, inflammatory cardiomyopathy, or electrophysiological abnormalities requiring intervention
Myocardial Diseases
Patients with various myocardial diseases including Fabry disease, Iron-overload, atrial fibrillation (AF), hypertension, aortic stenosis (AS), chronic myocardial infarction (MI), acute MI, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), arrhythmogenic cardiomyopathy (ACM), acute myocarditis, chronic myocarditis, cardiac amyloidosis, cardiac tumor, congenital heart disease, and suspected transplant rejection.
Interventions
Participants in this arm undergo a single, standardized cardiac MRI scan with gadolinium-based contrast agent.
Eligibility Criteria
The study population comprises a diverse cohort of patients with a comprehensive spectrum of myocardial conditions, including Fabry disease, iron overload, atrial fibrillation, hypertension, aortic stenosis, chronic and acute myocardial infarction, hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathies, acute and chronic myocarditis, cardiac amyloidosis, cardiac tumors, congenital heart disease, and cases of suspected transplant rejection. This population represents a wide array of pathophysiological processes affecting the myocardium, ensuring broad clinical relevance and generalizability of the study findings.
You may qualify if:
- Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.
- Specific disease categories include:
- Cardiomyopathies (HCM, DCM, RCM, ACM)
- Infiltrative disorders (cardiac amyloidosis, Fabry disease)
- Inflammatory conditions (acute/chronic myocarditis)
- Ischemic heart disease (acute/chronic MI)
- Valvular heart disease (aortic stenosis)
- Arrhythmic conditions (atrial fibrillation)
- Metabolic disorders (iron-overload)
- Neoplastic conditions (cardiac tumors)
- Congenital heart disease
- Post-transplant evaluation
- All diagnoses must be confirmed using established guideline-based criteria:
- Echocardiographic parameters meeting disease-specific cutoffs
- Cardiac MRI findings consistent with current consensus criteria
- +2 more criteria
You may not qualify if:
- Presence of multiple cardiomyopathy diseases or risk factors simultaneously
- Contraindications to CMR examination
- Poor image quality precluding accurate T1 mapping analysis
- Incomplete clinical data for definitive diagnosis confirmation
- Pregnancy or lactation
- Inability to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100000, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Department Director
Study Record Dates
First Submitted
December 29, 2025
First Posted
January 21, 2026
Study Start
March 1, 2020
Primary Completion (Estimated)
October 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
January 21, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share